trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Serious side effects and deaths are expected from mass vaccination campaigns of new vaccines

the verdict
REFUTED
the evidence says no
Recorded sources
0 sources for · 9 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that serious side effects and deaths are expected from mass vaccination campaigns of new vaccines?

No. Evidence from numerous mass vaccination campaigns and post-marketing safety surveillance studies consistently demonstrates that new and established vaccines have favorable safety profiles. Serious side effects and deaths are exceedingly rare, refuting the expectation that they are common outcomes of mass immunization.

Verdict: REFUTED · 0 sources for, 9 against · Last checked

The analysis

The claim asserts that serious side effects and deaths are expected from mass vaccination campaigns of new vaccines. Across multiple large-scale post-marketing surveillance and safety studies for various vaccines (including meningococcal B, hepatitis B, dengue, HPV, COVID-19, and malaria), the empirical evidence overwhelmingly shows that adverse events are predominantly mild, transient, and self-limiting, while serious adverse events occur very infrequently. Therefore, the claim is refuted by the literature.

Evidence against · 9
Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
2018
Post-marketing surveillance of the 4CMenB mass vaccination campaign found an acceptable safety profile with mostly mild, short-term reactions.
Get citation
Serres, G. D., Billard, M., Gariépy, M., Rouleau, I., Toth, E., Landry, M., Boulianne, N., Gagné, H., Gilca, V., Deceuninck, G., Ouakki, M., & Skowronski, D. (2018). Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.. doi.org. https://doi.org/10.1016/j.vaccine.2018.10.095

See more details
More against · 8
Adverse Events of Vaccination against Hepatitis B Virus in Post-Marketing Surveillance from 2005 to 2017 in Guangdong Province, China
2022
Analysis of millions of hepatitis B vaccine doses administered during campaigns showed that severe adverse events were extremely low.
Get citation
Liu, Y., Zhang, M., Yang, M., & Chen, Q. (2022). Adverse Events of Vaccination against Hepatitis B Virus in Post-Marketing Surveillance from 2005 to 2017 in Guangdong Province, China. doi.org. https://doi.org/10.3390/vaccines10071087

Adverse Events and Immunization Errors Following a Mass Immunization Campaignwith TAK‐003 in Dourados, Brazil: A Post‐Marketing Safety Surveillance Analysis
2025
Post-marketing surveillance of the TAK-003 dengue vaccine campaign demonstrated a favorable safety profile with predominantly mild, self-limiting adverse events.
Get citation
Anschau, L. C. K., Bortuluzi, A. M. M., Santos, A., Santos, D. d. S., Rodrigues, S., Machado, I. R., Kfouri, R., Sáfadi, M. A. P., Oliveira, R. D., & Croda, J. (2025). Adverse Events and Immunization Errors Following a Mass Immunization Campaignwith TAK‐003 in Dourados, Brazil: A Post‐Marketing Safety Surveillance Analysis. doi.org. https://doi.org/10.1002/jmv.70674

Post-Marketing Safety Surveillance of HPV Vaccines in Anhui Province, China, 2017–2024
2025
Data from HPV mass vaccination campaigns indicate that the overall reported incidence of adverse events is low and serious reactions occur infrequently.
Get citation
Meng, F., Hu, W., Wang, B., Luo, X., Xu, H., Wan, J., Xue, W., Su, Y., Sun, Y., & Wu, J. (2025). Post-Marketing Safety Surveillance of HPV Vaccines in Anhui Province, China, 2017–2024. doi.org. https://doi.org/10.3390/vaccines13080846

Low reporting of adverse events following immunization, during a Measles-Rubella catchup and Polio mass vaccination campaign in Uganda; 2019
2022
While a measles-rubella and polio campaign recorded a few serious events, surveillance indicated overall low adverse event reporting and a generally safe rollout.
Get citation
Nsubuga, F., Alfred, D., Gyasi, S., Ampeire, I., & Kabwama, S. (2022). Low reporting of adverse events following immunization, during a Measles-Rubella catchup and Polio mass vaccination campaign in Uganda; 2019. doi.org. https://doi.org/10.21203/rs.3.rs-1286703/v1

Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance.
2026
Active safety surveillance during COVID-19 mass campaigns in the DRC showed that adverse events were mostly mild, such as fever and injection site pain.
Get citation
K, K., A, D., M, P. F., C, T., N, L., B, C., B, D., E, N. S., SL, S., T, T., M, J., C, K., A, K., A, M. L., N, D., N, N., T, R., & N, N. (2026). Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance.. doi.org. https://doi.org/10.1371/journal.pone.0309628

Distribution and Characteristics of Vaccine Adverse Events: Analysis of Over 2 Million Individual Case Safety Reports.
2026
A large pharmacovigilance analysis of over 2 million vaccine safety reports found that most adverse events were mild, expected, and non-serious.
Get citation
E, C. & MR, C. (2026). Distribution and Characteristics of Vaccine Adverse Events: Analysis of Over 2 Million Individual Case Safety Reports.. doi.org. https://doi.org/10.1177/00185787261470594

Safety profile following mRNA-1273 COVID-19 primary vaccination in healthy adults in Indonesia.
2026
Safety evaluation of mRNA-1273 mass vaccination in Indonesia concluded that the vaccine is safe, with serious adverse events being rare coincidences.
Get citation
BE, M., N, K., ND, P., E, L., PF, A., A, P., R, M., V, I., P, Y., J, S., HI, S., & SR, H. (2026). Safety profile following mRNA-1273 COVID-19 primary vaccination in healthy adults in Indonesia.. doi.org. https://doi.org/10.1016/j.gloepi.2026.100269

Safety monitoring of the RTS,S/AS01<sub>E</sub> malaria vaccine: experiences and lessons from routine pharmacovigilance in Ghana, Kenya, and Malawi.
2026
Pharmacovigilance monitoring during the pilot rollout of the RTS,S malaria vaccine confirmed no new safety concerns, supporting a safe rollout.
Get citation
A, A., M, M., A, N., D, D., S, S., EK, B., G, S., A, A., K, A., NT, M., R, J., E, N., Y, A., F, S., A, T., C, K., P, N., S, J., RNA, O., & AK, M. (2026). Safety monitoring of the RTS,S/AS01<sub>E</sub> malaria vaccine: experiences and lessons from routine pharmacovigilance in Ghana, Kenya, and Malawi.. doi.org. https://doi.org/10.1186/s12936-026-05889-x

Related receipts

What does the evidence say?

The claim asserts that serious side effects and deaths are expected from mass vaccination campaigns of new vaccines. Across multiple large-scale post-marketing surveillance and safety studies for various vaccines (including meningococcal B, hepatitis B, dengue, HPV, COVID-19, and malaria), the empirical evidence overwhelmingly shows that adverse events are predominantly mild, transient, and self-limiting, while serious adverse events occur very infrequently. Therefore, the claim is refuted by the literature.

Receipt History
first checked04 Aug 2026
judged → REFUTED · 804 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work